Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.842 EUR 1.88% Market Closed
Market Cap: 152.5m EUR

Innate Pharma SA
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Innate Pharma SA
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Innate Pharma SA
PAR:IPH
Other
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Other
-€18.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Other
-€260k
CAGR 3-Years
60%
CAGR 5-Years
47%
CAGR 10-Years
-7%
Inventiva SA
PAR:IVA
Other
€5.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Other
-€2.3m
CAGR 3-Years
-6%
CAGR 5-Years
0%
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Other
€538k
CAGR 3-Years
N/A
CAGR 5-Years
79%
CAGR 10-Years
N/A

Innate Pharma SA
Glance View

Market Cap
149.1m EUR
Industry
Biotechnology

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

IPH Intrinsic Value
HIDDEN
Show

See Also

Back to Top